Momenta Pharmaceuticals, Inc., a leading biotechnology company headquartered in the United States, focuses on developing novel therapies for autoimmune diseases and rare disorders. Founded in 2001, Momenta has made significant strides in the industry, particularly with its innovative approach to monoclonal antibodies and complex generics. The company is renowned for its core product, M923, a biosimilar to a well-established therapeutic antibody, which exemplifies its commitment to providing high-quality, affordable treatment options. Momenta's unique expertise in molecular characterisation and analytical development sets it apart in the competitive biopharmaceutical landscape. With a strong market position, Momenta has achieved notable milestones, including successful collaborations and advancements in its pipeline, reinforcing its reputation as a pioneer in the biotechnology sector.
We don't have data for Momenta Pharmaceuticals, Inc., but we can show you information about their parent organization instead.
View parent company